Photoreceptor ciliopathies constitute the most common molecular mechanism of the childhood blindness Leber congenital amaurosis. Ten patients with Leber congenital amaurosis carrying the c.2991+1655A>G allele in the ciliopathy gene centrosomal protein 290 (CEP290) were treated (ClinicalTrials. gov no. NCT03140969) with intravitreal injections of an antisense oligonucleotide to restore correct splicing. There were no serious adverse events, and vision improved at 3 months. The visual acuity of one exceptional responder improved from light perception to 20/400.
. The more common molecular mechanisms of LCA involve a primary ciliopathy of rod and cone photoreceptors. A deep intronic allele (c.2991+ 1655A> G) is a frequent cause of LCA ciliopathies due to CEP290 (Centrosomal protein 290) mutations 3 . This allele results in a classic splicing defect, creating a premature truncation codon p.(Cys998*), probably subjecting the transcript to nonsense-mediated decay. Most patients lose all rod photoreceptors 4 but retain a central island of poorly functioning cone photoreceptors (Fig. 1a) over many decades 5 , thereby creating an opportunity for therapy. An antisense oligonucleotide (AON) was designed to restore correct splicing in the retina 6 ( Fig. 1b) , and we are assessing its safety and tolerability in a clinical trial involving intravitreal injections (ClinicalTrials.gov no. NCT03140969). Substantial improvement in vision in one patient prompted the decision to perform interim analyses of all data. Ten subjects were injected at least once and up to four times (Supplementary Tables 1 and 2 ); eight subjects had at least 3 months and four subjects had at least 6 months of follow-up after the first injection. There were no severe adverse events, and no events met stopping criteria. There was no intraocular inflammation: ocular treatment emergent adverse events were mild to none (Supplementary  Tables 4 and 5 ). There were no retinal changes apparent during the 3 months after the first injection on cross-sectional (Extended Data Fig. 1 ) or en face imaging (Extended Data Fig. 2 ).
Visual acuity is a standard method to evaluate efficacy. Baseline visual acuities ranged from 1.1 log 10 minimum angle of resolution (MAR) to light perception in study eyes to 0.7 log 10 MAR to light perception in untreated contralateral eyes (Supplementary Table 1) . After 1 month, there were no changes in visual acuity; at 3 months, one patient had a large (2.7 log 10 MAR) improvement, and four other patients had smaller improvements from baseline that were equal to or greater than the 0.3 log 10 MAR commonly considered clinically meaningful (Fig. 1d) . Interocular comparison at baseline showed treated eyes to be 0.12 log 10 MAR (6 letters) worse than untreated eyes; by 3 months after intervention, however, interocular asymmetry reversed, and treated eyes were 0.54 log 10 MAR (26 letters) better than untreated eyes (Extended Data Fig. 3c ). Statistical analysis showed a significant effect at 3 months after treatment. At 3 months, subjects received a second injection (Supplementary Table 1 ). Six subjects had data to months 4 and 5 and four subjects to month 6. Improvements over baseline were retained at 6 months (Extended Data Fig. 3 ).
Patients with LCA tend to show oculomotor instability ranging from fine nystagmus to large amplitude 'wandering' eye movements 5 . Consistent with some clinical observations, imaging of the eyes at 3 months showed a tendency towards improved ocular stability of treated eyes when presented with a fixation light but not when in a darkened room without fixation (Extended Data Fig. 4 ). The average improvement was 0.13 log mm at 3 months and grew to 0.27 log mm at 6 months. The 6-month time point showed a significant effect.
To better quantify changes in photoreceptor function due to intervention, the intensities of dimmest lights detected in the dark were evaluated with full-field stimulus testing (FST). Before intervention, seven of eight patients demonstrated light thresholds ranging from − 2.2 to 3.3 log 10 cd m −2 for red, and from − 2.5 to 2.3 log 10 cd m −2 for blue flashes (Extended Data Fig. 5 ). Chromatic differences were consistent with detection by cone photoreceptors at baseline in all patients but patient 7 (P7), who had function mediated by rod photoreceptors. By 2 and 3 months, both red and blue thresholds Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect Artur V. Cideciyan 1 showed improvements in many treated eyes (Fig. 1e,f) . At baseline, there was symmetry between the eyes, with interocular differences averaging less than 0.02 log 10 . After the injections, an interocular asymmetry developed by 3 months, favoring better thresholds in treated eyes (− 0.37 ± 0.72 log 10 for red, − 0.82 ± 0.83 log 10 for blue, respectively; Extended Data Fig. 5e,f) . Statistical analysis showed a significant effect at months 1, 2, 3, and 6 (Extended Data Fig. 5 ).
CEP290 ciliopathy is well known to affect the anatomy of photoreceptors 4, 5 . Changes to photoreceptor cilial anatomy were studied with cross-sectional images from a subset of patients with analyzable data at the fovea (Extended Data Fig. 6 ). P2 had foveal atrophy and evidence on microperimetry for fixation located in the temporal parafovea of the treated eye. P4 and P7 showed an apparent increase in the reflection originating near the junction between the inner and outer segments (Extended Data Fig. 6c) , and P7 showed lengthening of inner and outer segments (Extended Data Fig. 6e ). Such findings were not seen in the untreated eyes (Extended Data Fig. 6b,d,f) .
Functional vision was assayed with a multiluminance mobility course. Mobility scores showed a tendency for improvement at 2 and 3 months, but changes were mostly symmetric between the eyes and there was no significant effect (Extended Data Fig. 7) .
P2 was an exceptional responder who first reported substantial visual improvements 6 weeks after treatment. These findings led to a series of additional research studies. One year previously, P2 had visual acuities of light perception in both eyes. At baseline, vision in both eyes remained at light perception (Fig. 2a) . The standard Early Treatment Diabetic Retinopathy Study (ETDRS) letter acuity chart at 1 m, and all of the Berkeley Rudimentary Vision Test cards at 1 and 0.25 m, were not seen by either eye. At 1 month after the 160-µ g dose, visual acuities remained at light perception (Fig. 2a) . At 6 weeks, the patient self-reported that, for the first time in decades, lights were seen with increasing clarity and brightness, but only in the treated eye.
At month 2, the patient could read the first 3 lines of the standard ETDRS chart at 1 m with the treated eye (corresponding to a visual acuity of 1.46 log 10 MAR or Snellen equivalent of 20/580) but could not distinguish any letters with the untreated eye, which remained at light perception (Fig. 2a) . Over the next 4 months, including an intervening maintenance dose of 80 µ g after the 3-month visit, there was incremental increase in acuity to 1.28 log 10 MAR (Fig. 2a) . To better localize the retinal origin of the improved acuity, we used a modified microperimeter and stimulated the macula directly. With the treated eye at the 2-month visit, the patient was able to distinguish orientation of achromatic gratings at 1.37 log 10 MAR similar to the standard ETDRS results supporting a macular origin for improved acuity (Fig. 2a) . Chromatic gratings were used to distinguish between photoreceptor types mediating acuity. With red stimuli, the patient was able to distinguish orientation of gratings at 1.50 log 10 MAR, whereas with blue stimuli he could only see gratings at 1.97 log 10 MAR (Fig. 2b) . Between 3 and 6 months, chromatic acuities improved further (Fig. 2b) .
We used FST to evaluate detection of chromatic stimuli pre-and post-treatment in each eye under dark-and light-adapted conditions ( Fig. 2c-f) . Results indicated mediation by cone photoreceptors under both conditions at all visits, and in both eyes. Thresholds remained without change from baseline in the untreated eye, for all visits, all stimuli, and under different adaptation conditions. In the treated eye, however, there was an improvement in thresholds post-treatment compared with baseline. Threshold changes at 6 months were 0.71 and 0.55 log 10 units for red FSTs under dark-and light-adapted conditions, respectively, and 1.21 and 0.77 log 10 units for blue FSTs under dark-and light-adapted conditions, respectively. Statistical analysis showed a significant effect at all post-treatment visits for darkadapted conditions (Fig. 2c,d ) and all visits except for month 1 for light-adapted conditions (Fig. 2e,f) . Importantly, the large improvements of P2 were not the sole driver of the significance of the clinical trial cohort. Removing P2 from the analyses did not change the main , the mutation creates a strong splice donor site, and aberrant splicing results in the insertion of a cryptic Exon X in many CEP290 mRNA transcripts. Exon X contains a premature stop codon, predicted to result in an inactive, truncated CEP290 protein and/or to target the mutant mRNA transcript for nonsense-mediated decay, significantly lowering the levels of wild-type CEP290 protein. With treatment (right), QR-110 binds to the pre-mRNA and blocks aberrant splicing, thereby skipping Exon X in mRNA, resulting in increased levels of wild-type transcripts and CEP290 protein. c, Injection into the vitreous humor. d-f, Change in log 10 units from baseline of visual acuity and FST using red and blue flashes presented in the dark. All three measures of visual function show significant improvements in treated eyes at 3 months. Larger symbols are averages from ten patients at baseline and month 1, and 8 patients at months 2 and 3. Smaller symbols are individual data points. Error bars, ± 1 s.d. BL, average of two pretreatment baselines; M1-M3, post-treatment evaluations at months 1-3 after the administration of an intravitreal dose of 160 or 320 µ g after baseline. Linear mixed-effects models were used for the statistical analysis.
statistical conclusion supporting significant improvements of visual acuity and FST at 3 months (Supplementary Table 3) .
Advancing from an era of identifying causative genes in LCA, we are now using this information to design molecular-based therapies for these otherwise incurable forms of blindness. We now report that a primary photoreceptor ciliopathy can show improvement in vision using an AON therapy targeting pre-mRNA splicing. The improvement is noticeable to the patients and quantifiable with a number of outcome measures. Many questions remain as to the longevity of the efficacy and the value and safety of further dosage, but this evidence of positive visual change is a large translational step to the clinic for a childhood blindness with a wide window of therapeutic opportunity 5 .
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Methods
Study medication and trial design. QR-110 is a 17-mer RNA AON consisting of the 5' to 3' sequence GGUGGAUCACGAGUUCA prepared as the sodium salt (C 180 H 219 N 67 Na 16 O 101 P 16 S 16 and molecular mass of 6,313.51 Da). QR-110 drug substance was manufactured with all RNA bases 2'-O-methylribose modified with all inter-nucleotide linkages comprising phosphorothioate (BioSpring GmbH). QR-110 was synthesized as Good Manufacturing Practices (GMP) grade by solid-state synthesis in the direction 3′ to 5′ and further purified by ion-exchange chromatography. Drug product was prepared by dissolving QR-110 drug substance (10 mg ml -1 ) in formulated PBS in depyrogenated vials and sterilized stoppers, and filter sterilized using 0.22-μ m double filtration (Pyramid Laboratories).
QR-110 was designed to bind to a sequence within the exonic splicing enhancer sequence at intron 26 of the CEP290 pre-mRNA 6 . The hybridization of QR-110 is thought to modulate the RNA splicing process, blocking access to the active cryptic splicing site and restoring preference for the wild-type splicing sites. A resulting increase of wild-type mRNA transcript leads to an increase of functional CEP290 protein 6 . An open-label, multiple-arm, multiple-dose, dose-escalation study was designed to evaluate the safety and tolerability of QR-110 administered via unilateral intravitreal injection (to the worse eye) every 3 months for up to 1 year (ClinicalTrials.gov no. NCT03140969). The study is being conducted according to the Declaration of Helsinki as well as according to the principles of Good Clinical Practice. There are three sites (Iowa City, USA; Philadelphia, USA; and, Ghent, Belgium), and the Institutional Review Boards of the University of Pennsylvania, Wills Eye Hospital, the University of Iowa, and Ghent University approved the studies which complied with all relevant ethical regulations. Eligible subjects include males and females aged 6 years or older at screening, with a clinical diagnosis of LCA and a molecular diagnosis of homozygosity or compound heterozygosity for the CEP290 p.(Cys998*) mutation. Of note, inclusion criteria for best-corrected visual acuity are better than or equal to light perception in both eyes, and equal to or worse than + 0. Table 1 ). Written informed consent (or informed assent and parental consent for pediatric subjects) was provided by each subject before the initiation of study activities. Ophthalmic and systemic safety aspects of the study were and continue to be monitored by an independent data monitoring committee. There were 6 adult patients between the ages of 19 and 44 years, and 4 pediatric patients between 8 and 16 years. There were five males and five females. All subjects were compound heterozygotes for the c.2991+ 1655A> G p.(Cys998*) allele and an additional mutant allele in the CEP290 gene. Two patients were siblings, and two patients carried the same mutations but were not known to be related. Subjects were assigned to receive one of two dose levels of QR-110. Three adult and 2 pediatric patients were assigned to a loading dose of 160 µ g and a maintenance dose of 80 µ g QR-110. Three adult patients and 2 pediatric patients were assigned to a dose consisting of 320/160 µ g QR-110 (Supplementary Tables 1 and 2 ). Safety evaluations. Ocular safety was assessed with standard eye examinations, including gradings of the anterior and posterior segment according to the Standardization of Uveitis Nomenclature 7 , and of the lens according to the Age-Related Eye Diseases Study Clinical Lens Grading System 8 . Near-infrared excited autofluorescence imaging, when possible, was used to document any changes in RPE pigmentation 9 . Systemic safety was evaluated with physical examinations at baseline and postoperative visits. Routine hematology; testing of serum chemistry, prothrombin time (with international normalized ratio), and partial thromboplastin time; and urinalysis were performed at baseline and postoperatively.
Visual acuity. Visual acuity was measured using ETDRS methodology 10 at 2 baseline visits and postinjection visits starting at month 1. Best-corrected visual acuity was scored as the number of letters correctly read after adjusting for distance (4 m or 1 m) and expressed as log 10 MAR to measure the range of acuities from 20/10 to 20/800 (or from − 0.30 to + 1.6 log 10 MAR). For patients not able to correctly read ETDRS letters at 1 m, the Berkeley Rudimentary Vision Test battery was performed 11 at distances of 1 m and 0.25 m to measure the range of acuities from 20/500 to 20/16,000 (or from + 1.4 to + 2.9 log 10 MAR). Hand-motion acuity was assigned + 3.0 log 10 MAR and light perception was assigned + 4.0 log 10 MAR.
Imaging. Spectral-domain optical coherence tomography was used to obtain cross-sectional imaging of the retina 4,5 (RTVue-100, Optovue, or Spectralis, Heidelberg Engineering). All optical coherence tomography images were aligned by straightening the major RPE reflection. In a subset of 4 patients, with reliable foveal scans available in both eyes at baseline, month 1, and month 3 time points, quantitative analyses of the photoreceptor cilial anatomy was performed using longitudinal reflectivity profiles. Inner segment length was estimated between the outer limiting membrane peak and the peak originating near the junction of inner and outer segments (IS/OS). The outer segment length was estimated between the IS/OS peak and the peak originating near the interface of the outer segment tips and apical RPE processes. En face imaging with near-infrared illumination was performed with autofluorescence mode or reflectance mode using a confocal scanning laser ophthalmoscope 4, 5, 9 (HRA2 or Spectralis, Heidelberg Engineering).
Oculomotor control and instability. To account for the wide spectrum of oculomotor abnormalities encountered in CEP290-LCA patients, an infrared video oculography method was used 5 . Two recordings were performed in a darkened room-one with a bright fixation light available along the primary gaze, and another without a fixation light.
FST. Sensitivity to chromatic light flashes presented in the dark in dark-adapted eyes was measured with FST developed specifically for patients with severe vision loss and oculomotor instability 12 . FST was tested with a commercial software 13, 14 . For each color, eye, and visit, approximately 12 independent thresholds were obtained, thus providing an estimate of intra-session variability. Large variability in FST usually indicates unreliable performance within a session. Exploratory analyses showed that 11 sessions (of 197) were associated with unusually large intra-session variances compared with previously published estimates of variability 12 . These sessions had intra-session s.d. > 1.01 log 10 and were also classified as suspected outliers by Tukey's criteria (1.5 × interquartile range above the third quartile). Statistical analyses were performed twice: once with the full data set and a second time excluding the 11 sessions. Both analyses, with and without exclusions, supported the same statistical conclusions regarding a significant treatment effect from months 1 to 6; however, exclusion allowed presentation of the most conservative, internally consistent, and repeatable data. Of additional note, at the 3-month time point it was found that one patient (P7) was mistakenly tested with a 'flash' stimulus (duration < 4 ms) instead of the 'pulse' stimulus (duration = 200 ms) specified in the protocol. At the 3-month time point, the patient was tested with both types of stimuli to obtain a comparison.
Mobility. The visual navigation challenge (VNC) course (ORA) was used to assess mobility performance of patients at multiple levels of luminance 15 . There were 4 difficulty levels of the courses, and each course had several lighting conditions defining 20 'levels. ' For each level, there were several combinations of random obstacle placements that were used to avoid learning effects. A level of 0 represented failing to pass successfully any of the courses at any light level; a level of 19 corresponded to passing the most difficult course under the dimmest light conditions. For each eye and each visit, the highest level course passed was recorded. Results from P7 were censored because of the unavailability of levels 13-19 at the time of both baseline visits. In addition, 1 of the baseline visits and the month 1 visit of P5 were censored for the same reason.
Additional evaluations in the exceptionally responding patient. P2 was known to the investigators and previously evaluated with detailed non-invasive assessments of visual function and retinal structure 4, 5 . Contemporaneous with the clinical trial, the patient was enrolled in additional research studies that had been approved by the University of Pennsylvania Institutional Review Board. The studies included FST under dark-and light-adapted conditions 12, 16 . Specifically, the custom thresholding algorithm was based on a 4-dB/2-dB staircase with 2 response reversals (as opposed to the binary thresholding algorithm used by the manufacturer). In addition, there was a limited response-acceptance window to minimize the effect of extraneous responses not synchronized with the stimulus presentation. Both of these algorithmic features helped reduce variability, especially in patients with severe vision loss. Spatial resolution was measured with achromatic and chromatic gratings 17 .
Statistical analyses. Linear mixed-effects models were used for the statistical analysis of all efficacy outcomes to account for the correlation structure and repeated measures within each data set. The baseline data were pooled from the two visits obtained before the first injection. Results from the two dose groups were pooled for statistical analyses. The models used an unstructured covariance matrix, restricted maximum likelihood estimation, and Satterthwaite's approximation for denominator degrees of freedom. Computations used the lme4 (ver. 1.1-17) 18 and lmerTest (ver. 3.0-1) 19 packages from R statistical software (ver. 3.4.4, 2018-03-15) 20 . For visual acuity, the dependent variable was the MAR expressed in log 10 MAR. The model used treatment-by-visit interactions as fixed effects. Intercept and visit were specified as random effects, with patient as the grouping factor. The treatment factor had 2 levels (treated and untreated eyes), and the visit factor had 7 levels (baseline and months 1, 2, 3, 4, 5, and 6). For OCI, the dependent variable was the variation of the radial distance of the center of the pupil from the mean normal primary gaze locus over 30 s expressed in log 10 mm. The fixed effects and random effects were the same except that the visit factor had 3 levels (baseline, month 3, and month 6). Separate analyses were performed for OCI data recorded with and without fixation. For FST, the dependent variable was the visual threshold expressed in log 10 phot-cd m -2 . The model used treatment-by-condition interactions as fixed effects in addition to treatment-by-visit. The condition factor had two levels (blue and red). The random effects were the same as in the visual acuity model. For mobility, the dependent variable was the performance score, an ordinal variable ranging from 0 to 19. The same analysis was used for mobility as for visual acuity by approximating the ordinal variable as a continuous variable. For  Fig. 2 , separate analyses were performed for dark-adapted and light-adapted data. Analyses were identical to those of all other FST results, except that random effects were not specified as there was only a single patient.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
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Extended Data
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted All studies must disclose on these points even when the disclosure is negative.
Sample size
We are reporting interim results from an ongoing first-in-man study. The clinical trial was designed for determining initial safety and feasibility, and as typical in rare diseases, 12 patients were planned to be enrolled in 3 centers. Current report is the interim analysis performed with 10 patients dosed at least once.
Data exclusions For FST, we performed two sets of analyses. One with no exclusions and another where 11 test sessions (out of 197) were excluded because they were associated with unusually large test-retest variances compared to previously published assessment of variability. Large test-retest variability in FST is usually associated with unreliable subject performance. A description of the method used to detect these sessions is included in the manuscript. Exclusion criterion was established after during the interim analyses. Both analyses, with and without exclusions, supported similar statistical conclusions regarding the treatment effect, however, exclusion allowed presentation of the most conservative, internally consistent and repeatable data.
Replication
This is an early Phase first-in-man clinical trial and there was no replication.
Randomization There was no randomization of eyes because the worse eye was treated per protocol. There was no randomization of dose because this was a dose escalation study.
Blinding
This is an early Phase trial. Masking was not possible since there was no placebo injection, and the injected eye was obvious to both the patients and the evaluating investigators.
Reporting for specific materials, systems and methods There were 10 patients included with two disease causing CEP290 mutations and a clinical diagnosis of autosomal recessive Leber congenital amaurosis (LCA). All patients had a common c.2991+1655A>G mutation, and a second mutation that varied between patients. There were 6 adult patients between the ages of 19 to 44 years, and 4 pediatric patients between 8 and 16 years. There were 5 males and 5 females. Three adult and 2 pediatric patients were assigned to a loading dose of 160 μg and a maintenance dose of 80 μg, and 3 adult patients and 2 pediatric patients were assigned to 320/160 μg.
Recruitment
Patients were recruited from the clinical practices of physician-investigators at the three centers or from their clinical collaborators. The rarity of this specific orphan disease led to this recruitment process. Enrollment only occurred if inclusion criteria were met and the patient expressed interest in participation, given full discussion of the protocol and risks. It is unknown whether there was any self-selection bias, and how such a bias may have impacted the results.
